MK-2060 explained

MK-2060 is an experimental monoclonal antibody and factor XI inhibitor in development as an antithrombosis agent.[1] [2] [3]

Notes and References

  1. Prakash . Swathi . Mares . Adriana C . Porres-Aguilar . Mateo . Mukherjee . Debabrata . Barnes . Geoffrey D . Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review . Vascular Medicine . 2023 . 10.1177/1358863X231206778.
  2. Prisco . Domenico . Mattioli . Irene . De Caterina . Raffaele . Bettiol . Alessandra . The new era of anticoagulation: factor XI and XII inhibitors . Bleeding, Thrombosis, and Vascular Biology . 7 June 2023 . 2 . 2 . 10.4081/btvb.2023.76. free .
  3. De Caterina . Raffaele . Prisco . Domenico . Eikelboom . John W . Factor XI inhibitors: cardiovascular perspectives . European Heart Journal . 21 January 2023 . 44 . 4 . 280–292 . 10.1093/eurheartj/ehac464.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MK-2060".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.